Cobalis Corp. is a development stage company. We are a specialty pharmaceutical company that has been focused on the development and FDA approval of PreHistin, a patented, over-the-counter drug product candidate intended to treat seasonal allergy suffers. Our recently completed twin Phase III trials were inconclusive. If these trials had been successful, we had intended to file an NDA in the second half of 2007 with the FDA for marketing over-the-counter to seasonal allergy suffers.
We are currently reviewing our PreHistin clinical trial data and are considering marketing strategies for PreHistin to determine if we will pursue additional clinical trials in seasonal allergies, investigate PreHistin for other indications, or undertake alternative strategies, including a national and global marketing strategy. PreHistin has indications for other atopic allergic diseases including atopic migraine, atopic dermatitis, food allergies and atopic asthma. However, we have not studied any other applications beyond seasonal allergies.
